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Introduction 
Pulmonary veno-occlusive disease (PVOD) is a rare variant 
of primary pulmonary hypertension (PPH) with a devastat- 
ing prognosis. In the National Institutes of Health registry 
on primary pulmonary hypertension, the median survival in 
PVOD was only 84 days after diagnosis (1). The 6-month 
mortality in this group was 71% (1). PVOD has been 
associated with high-dose chemotherapy, radiation and 
bone-marrow transplantation (24). In sporadic cases, there 
have been speculations about a causal role of viral infec- 
tions (5) but in most cases, an aetiological agent could not 
be identified. 
Apart from lung transplantation, no effective treatment 
has been described so far for PVOD. Vasodilators which 
have beneficial effects in some patients with PPH, can cause 
acute pulmonary oedema in PVOD, presumably because 
they lead to precapillary vasodilation while the venous 
outflow remains obstructed (6,7). However, inhaled vaso- 
dilators may be more effective and less dangerous in this 
group of patients. Here, we report for the first time on the 
haemodynamic effects of inhaled nitric oxide (NO) and 
aerosolized iloprost (a stable prostacyclin derivative) in a 
patient with histologically confirmed idiopathic PVOD. 
Our results show that both substances can have beneficial 
effects in this disease. 
Case Report 
The patient was a 24-year-old carpenter who was in excel- 
lent health until 2 years before admission. At this time, he 
felt that his exercise tolerance had decreased slightly, which 
he attributed to his nicotine consumption of 20 cigarettes 
per day. However, he developed progressive shortening of 
breath after he had stopped smoking and he went to see his 
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physician in June 1997. At this time, he felt marked 
dyspnoea on exertion and was not able to climb a flight of 
stairs without two or three breaks. 
His physician found severe arterial hypoxaemia and 
echocardiographical signs of pulmonary hypertension and 
referred the patient to another hospital. Here, a chest X-ray 
and a computed tomographic (CT) scan of the thorax 
revealed patchy ground-glass opacities, a characteristic 
finding in PVOD (8). Pulmonary function testing was 
normal except for a reduced diffusion capacity for carbon 
monoxide. Echocardiography showed right ventricular 
hypertrophy and dilatation, tricuspidal regurgitation, right 
atria1 dilatation, no patent foramen ovale and normal left 
atria1 and ventricular cavities. Right heart catherization 
confirmed the presence of severe pulmonary hypertension, 
and pulmonary angiography ruled out recurrent pulmonary 
embolism. An open lung biopsy was performed which 
revealed intimal fibrosis of different stages with partial 
occlusion of small pulmonary arteries and veins. Thus, a 
diagnosis of pulmonary veno-occlusive disease was made 
and the patient was referred to our hospital for further 
treatment. 
The patient was immediately accepted on the waiting list 
for double-lung transplantation. A trial of steroid treatment 
did not lead to clinical improvement. In regard of the 
extremely poor prognosis of PVOD and the average 
waiting-time for a suitable organ which is 12-18 months at 
our institution, we performed another right-heart catheter- 
ization to evaluate the effects of inhaled nitric oxide and 
aerosolized iloprost in this patient. This procedure was 
approved by our institutional ethics committee and the 
patient gave written informed consent. 
All measurements were performed while the patient was 
breathing through an inhalation device (raindrop nebulizer) 
that had been developed for the application of iloprost 
(Iloneb, Nebutec, Elsenfeld, Germany). Oxygen was added 
to the device at a constant flow of 3 1 min- ’ and the patient 
was wearing a nose clip throughout the procedure. After 
the baseline variables had been obtained, NO was added to 
the inspiratory limb of the device until an expiratory 
concentration of 40 ppm was reached. The NO concen- 
tration was measured using the electrochemical technique 
(MicroGas Nitric Oxide Monitor, Med In, Munich, 
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TABLE 1. Effects of nitric oxide (NO) and aerosolized iloprost in a patient with pulmonary 
veno-occlusive disease 
Baseline 
NO 
(40 ppm) 
O2 (1 min - ‘) 3 3 3 
Systemic arterial pressure (syst/diast/mean) 130/73/90 144176197 147/77/101 
Heart rate (beats min - ‘) 59 65 62 
Right atria1 pressure (mmHg) 3 3 3 
Pulmonary arterial pressure (syst/diast/mean) 76134148 81132148 77133147 
Pulmonary capillary wedge pressure (mmHg) 9 8 8 
Cardiac output (1 min - ‘) 45 5.3 5.6 
Cardiac index (1 min - i m - 2, 2.3 2.7 2.9 
Stroke volume (ml) 76.3 81.5 90.3 
Systemic vascular resistance (dynes s - i cm5) 1545 1417 1399 
Pulmonary vascular resistance (dynes s - ’ cm5) 710 603 557 
Arterial PO, (Torr) 61 176 124 
Arterial X0, (Torr) 33 34 33 
Arterial saturation (%) oxygen 93 99 99 
Mixed-venous saturation (%) oxygen 70 80 82 
Germany). The NO, concentration was not determined. 
After 10 min of inhaling NO at 40 ppm, a complete evalu- 
ation of haemodynamics and blood gases was performed. 
Thereafter, NO was discontinued. After the haemodynamic 
variables had returned to baseline again, inhalation of 
iloprost (Ilomedin’@. Schering AG, Berlin, Germany) was 
started. Iloprost (5Opg) was diluted in 6 ml of isotone saline 
and nebulized in the device described above, and the patient 
inhaled that solution until a maximum haemodynatnic 
effect was reached (10 min). The oxygen flow was kept 
constant throughout the procedure. 
The results of this procedure are shown in Table 1. At 
baseline, right-heart catherization revealed severe pul- 
monary hypertension with a normal pulmonary capillary 
wedge pressure and a well-preserved cardiac output. 
Inhaled NO at 40 ppm did not affect the pulmonary artery 
pressure but had a marked effect on arterial oxygenation 
and caused a moderate increase of the cardiac output 
accompanied by a decline of the pulmonary vascular resist- 
ance (- 15%). Aerosolized iloprost also did not affect 
the pulmonary artery pressure but had a beneficial effect on 
the arterial oxygen tension and was slightly more potent 
than NO in decreasing the pulmonary vascular resistance 
( - 22%). The pulmonary capillary wedge pressure did 
not change during the inhalation of NO or iloprost, 
respectively. 
The patient therefore received regular inhalations of 
iloprost in a total daily dose of 100,ug divided into six doses 
which he inhaled at 2-3 h intervals (each inhalation lasting 
lo-12 min) throughout the day. During the following days, 
he experienced a marked improvement of his exercise 
tolerance and relief from dyspnoea. One week after initia- 
tion of the treatment, the walking distance in the 6-min 
walking test increased from 200 m prior to the treatment 
to 320 m. Clinical or radiographical signs of increasing 
pulmonary oedema did not occur and the patient did not 
report adverse side-effects. 
The patient was discharged 1 week later receiving the 
same regimen of aerosolized iloprost and continued to feel 
markedly improved. Unfortunately, only 8 weeks there- 
after, he developed a high-grade fever and was admitted to 
another hospital where the diagnosis of systemic inflam- 
matory response syndrome was made. An aetiological agent 
could not be identified and, despite aggressive antibiotic 
treatment, septic multiorgan failure developed and the 
patient died a few days later. Autopsy confirmed the 
diagnosis of pulmonary veno-occlusive disease but failed to 
identify the source of the fatal sepsis. 
Discussion 
This is the first report to show the acute effects of inhaled 
NO and aerosolized iloprost in pulmonary veno-occlusive 
disease. As would have been expected from the histological 
findings of widespread intimal fibrosis in small pulmonary 
arteries and veins, both substances had almost no effect on 
the pulmonary arterial pressure. Nevertheless, there was a 
considerable increase in the cardiac output accompanied by 
a decline in the pulmonary vascular resistance, indicating 
that there was at least some regional vasodilation. The most 
impressive finding was the marked improvement in gas 
exchange with both substances which was probably caused 
by a combination of several mechanisms that are not fully 
elucidated. Unlike systemically applied vasodilators, which 
tend to deteriorate gas exchange in the diseased lung 
due to unselective vasodilation and impaired ventilation- 
perfusion matching, inhaled vasodilators are known to 
act preferentially in well-ventilated areas, thereby im- 
proving ventilation-perfusion matching and oxygenation. 
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Furthermore, it has been shown in patients with chronic 
obstructive pulmonary disease that the combined admin- 
istration of inhaled NO and oxygen improves the arterial 
oxygenation significantly more than inhaled NO or supple- 
mental oxygen alone (9). It has been suggested that a 
combination of the selective effects of NO together with an 
improved alveolar oxygenation (especially in areas with a 
low ventilationperfusion ratio) could be responsible for 
this finding (9). An analogue mechanism may play a role in 
PVOD where ventilation-perfusion matching is disturbed 
not only by the pulmonary vascular disease but additionally 
by the presence of local interstitial and intra-alveolar 
oedema (6,8,10). The CT findings in our patients also 
suggested the presence of patchy areas of pulmonary 
oedema and the improvement of the arterial oxygenation 
by the combined administration of inhaled vasodilators and 
oxygen could have resulted from the additive effects of 
redistribution of the blood flow and an increase of the 
alveolar oxygenation, particularly in those regions that 
were mostly affected by pulmonary oedema. 
Aerosolized iloprost has recently been described as a 
novel therapeutic regimen for patients with primary pul- 
monary hypertension (11). The efficacy of this therapy is 
currently being investigated in a German multicentre trial 
from which no data have been released so far. Patients 
usually receive a daily dose of IOO-15Opg which is delivered 
in 6-10 inhalations depending on the individual response. 
Sleep should not be interrupted by inhalations and, so far, 
major side-effects or rebound phenomena have not been 
recognized as important clinical problems (unpublished 
data). In Germany, the costs of this treatment are between 
100,000 and 150,OOODM per year which is comparable to 
the annual costs of continuous i.v. prostacyclin when the 
dose not exceeds 20 ng kg - ’ min - ‘. 
So far, there have been no reports on the administration 
of inhaled vasodilators in PVOD. In our patient, both 
inhaled NO and aerosolized iloprost had favourable effects 
on cardiac output, pulmonary vascular resistance and on 
blood gases, while the pulmonary capillary wedge pressure 
and the systemic blood pressure were not affected. 
Unfortunately, our patient died only 8 weeks after ilo- 
prost treatment had been initiated from septic multiorgan 
failure due to an unidentified micro-organism. We have no 
reason to assume that this complication was related to the 
treatment with aerosolized iloprost. In our centre, more 
than 40 patients are currently receiving long-term treatment 
with aerosolized iloprost for primary pulmonary hyperten- 
sion and infectious complications have not been observed in 
those patients (unpublished data). 
In conclusion, our findings suggest that inhaled NO and 
aerosolized iloprost may be considered for treatment of 
PVOD. It is not known whether these substances have a 
positive effect on the natural course of this fatal disease but 
our findings raise the hope that they may at least provide a 
temporary benefit that may be helpful in bridging the time 
gap until lung transplant can take place. 
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